| [1] |
|
| [2] |
|
| [3] |
Hammer A, Soegaard V, Maimburg RD, et al. Cervical cancer screening history prior to a diagnosis of cervical cancer in Danish women aged 60 years and older：a national cohort study [J]. Cancer Med， 2019， 8(1): 418-427. DOI: 10.1002/cam4.1926.
|
| [4] |
舒桐，李斌. 老年子宫颈癌的防控和诊疗策略[J]. 实用妇产科杂志，2019, 35(8): 561-563.
|
| [5] |
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines): older adult oncology. version 2.2025[EB/OL]. [2025-05-14].
URL
|
| [6] |
Xu Y, Ji T, Li X, et al. The effectiveness of the comprehensive geriatric assessment for older adults with frailty in hospital settings: a systematic review and Meta-analysis [J]. Int J Nurs Stud, 2024, 159: 104849. DOI: 10.1016/j.ijnurstu.2024.104849.
|
| [7] |
|
| [8] |
Xie S, Pan S, Zou S, et al. Characteristics and treatments of patients aged 65 years or over with cervical cancer [J]. Clin Interv Aging, 2020, 15: 841-851. DOI： 10.2147/CIA.S255305.
|
| [9] |
Gu Y, Cheng H, Cang W, et al. Comparison of oncological outcomes in elderly early-stage cervical cancer patients treated with radical surgery or radiotherapy: a real-world retrospective study with propensity score matching [J]. Front Oncol, 2023, 13: 1019254. DOI： 10.3389/fonc.2023.1019254.
|
| [10] |
Schmeler KM, Pareja R, Lopez Blanco A, et al. ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer [J]. Int J Gynecol Cancer, 2021, 31(10): 1317-1325. DOI： 10.1136/ijgc-2021-002921.
|
| [11] |
Chen W, Xia X, Xie X, et al. Nomogram for prognosis of elderly patients with cervical cancer who receive combined radiotherapy [J]. Sci Rep, 2023, 13(1): 13299. DOI： 10.1038/s41598-023-39764-5.
|
| [12] |
Hata M. Radiation therapy for elderly patients with uterine cervical cancer：feasibility of curative treatment [J]. Int J Gynecol Cancer, 2019, 29(3)：622-629. DOI： 10.1136/ijgc-2018-000077.
|
| [13] |
Hou P, Hsieh C, Wei M, et al. Differences in treatment outcomes and prognosis between elderly and younger patients receiving definitive radiotherapy for cervical cancer [J]. Int J Environ Res Public Health， 2020， 17(12)：4510. DOI： 10.3390/ijerph17124510.
|
| [14] |
Rodrigues MJ, Zapardiel I, Frélaut M, et al. A call for specific geriatric data on cervical cancers [J]. Future Oncol, 2016, 12(9): 1101-1104. DOI： 10.2217/fon-2016-0022.
|
| [15] |
Trifanescu OG, Gales LN, Serbanescu GL, et al. Long-term oncological outcome in patients with cervical cancer after 3 trimodality treatment (radiotherapy, platinum-based chemotherapy, and robotic surgery)[J]. Medicine, 2021, 100(13): e25271. DOI: 10.1097/MD.0000000000025271.
|
| [16] |
Shimamoto K, Saito T, Kitade S, et al. A study of treatments and outcomes in elderly women with cervical cancer [J]. Eur J Obstet Gynecol Reprod Biol, 2018, 228: 174-179. DOI: 10.1016/j.ejogrb.2018.06.032.
|
| [17] |
Penson RT， Huang HQ， Wenzel LB，et al. Bevacizumab for advanced cervical cancer：patient-reported outcomes of a randomised，phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240)[J]. Lancet Oncol， 2015， 16(3)：301-311. DOI： 10.1016/S1470-2045(15)70004-5.
|
| [18] |
Wang W， Hou X， Yan J，et al. Outcome and toxicity of radical radiotherapy or concurrent chemoradiotherapy for elderly cervical cancer women [J]. BMC Cancer， 2017， 17(1)：510. DOI： 10.1186/s12885-017-3503-2.
|
| [19] |
Nosaka K， Shibata K， Utsumi F，et al. Feasibility and benefit of concurrent chemoradiotherapy for elderly patients with uterine cervical cancer [J]. Tumori， 2016， 102(6): 600-605. DOI： 10.5301/tj.5000530.
|
| [20] |
Mitsuhashi A, Uno T, Usui H, et al. Daily low-dose cisplatin-based concurrent chemoradiotherapy in patients with uterine cervical cancer with emphasis on elderly patients: a phase 2 trial [J]. Int J Gynecol Cancer, 2013, 23(8): 1453-1458. DOI: 10.1097/IGC.0b013e3182559bda.
|
| [21] |
Liu CH， Kung YH， Chien-Fu LJ，et al. Synergistic therapeutic effect of low-dose bevacizumab with cisplatin-based chemotherapy for advanced or recurrent cervical cancer [J]. J Chin Med Assoc, 2021, 84(12): 1139-1144. DOI： 10.1097/JCMA.0000000000000629.
|
| [22] |
中国抗癌协会宫颈癌专业委员会，李晶，林仲秋. 子宫颈癌抗血管生成药物临床应用指南(2023年版) [J]. 中国实用妇科与产科杂志， 2023, 39(12): 1201-1209. DOI: 10.19538/j.fk2023120113. |
| [23] |
|
| [24] |
Kahraman S, Erbas UE, Yalcin B. Who should be treated with pembrolizumab in addition to standard of care in advanced cervical cancer？[J]. Med Oncol， 2022， 39(3)：33. DOI： 10.1007/s12032-021-01623-6.
|
| [25] |
Da Silva DM， Enserro DM， Mayadev JS，et al. Immune activation in patients with locally advanced cervical cancer treated with ipilimumab following definitive chemoradiation(GOG-9929)[J]. Clin Cancer Res， 2020， 26(21)：5621-5630. DOI： 10.1158/1078-0432.CCR-20-0776.
|
| [26] |
Garcia-Duran C， Grau F， Villacampa G，et al. ATOMICC trial: a randomized, open-label, phase Ⅱ trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation [J]. Int J Gynecol Cancer, 2022, 32(9): 1196-1200. DOI: 10.1136/ijgc-2022-003370.
|
| [27] |
Lorusso D, Xiang Y, Hasegawa K, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial [J]. Lancet, 2024, 403(10434): 1341-1350. DOI: 10.1016/S0140-6736(24)00317-9.
|
| [28] |
Chen J, Li C, Cao Y, et al. Toripalimab combined with concurrent platinum-based chemoradiotherapy in patients with locally advanced cervical cancer：an open-label，single-arm，phase Ⅱ trial [J]. BMC Cancer, 2022, 22(1): 793. DOI: 10.1186/s12885-022-09866-w.
|
| [29] |
O′Malley DM, Oaknin A, Monk BJ, et al. Phase Ⅱ study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer [J]. Gynecol Oncol， 2021， 163(2)：274-280. DOI: 10.1016/j.ygyno.2021.08.018.
|
| [30] |
Colombo N， Dubot C， Lorusso D，et al. Pembrolizumab for persistent，recurrent, or metastatic cervical cancer [J]. N Engl J Med, 2021, 385(20): 1856-1867. DOI: 10.1056/NEJMoa211243.
|